Cara Therapeutics to Present at the Jefferies Healthcare Conference
01 Juin 2023 - 1:00PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus, today
announced that Christopher Posner, President and Chief Executive
Officer, will present at the Jefferies Healthcare Conference on
Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.
A webcast of the presentation can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com. An
archived webcast recording will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s KORSUVA® (difelikefalin) injection is the first and only
FDA-approved treatment for moderate-to-severe pruritus associated
with chronic kidney disease in adults undergoing hemodialysis. The
Company is developing an oral formulation of difelikefalin and has
Phase 3 programs ongoing for the treatment of pruritus in patients
with non-dialysis dependent advanced chronic kidney disease and
atopic dermatitis. In addition, the Company has initiated a Phase
2/3 program of oral difelikefalin for the treatment of
moderate-to-severe pruritus in patients with notalgia paresthetica.
For more information, visit www.CaraTherapeutics.com and follow the
company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cara Therapeutics (NASDAQ:CARA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024